Dried blood spots (DBS) have been used for many years in neonatal testing using either a heel or finger prick onto a piece of paper which is then dried and shipped for analysis. This approach has now been applied to the field of bioanalysis in preclinical, toxicokinetic, and clinical studies. DBS has several benefits, namely:
The use of low sample volumes allows pediatric sampling, improves study recruitment
All toxicokinetic data can be derived from samples from one animal, improving data quality
Reduces cost in animals, procedures and test substances
Cards can be stored at ambient conditions, reducing sample storage and transport costs
One major difference between the neonatal studies and bioanalytical studies is the rigorous quantitative nature of the bioanalytical studies. Although there are many benefits of the DBS approach for the bioanalyst, both ethical and financial, the use of DBS involves a reconsideration of current workflows. Notably, the small volumes typical of the DBS sample require highly-sensitive LC/MS/MS assays. Thus, the area of dried blood spot analysis is attracting a significant amount of research into best practices.
In this webinar, hear from experts in the field about the challenges and solutions associated with DBS analysis and promising analytical solutions to address them, with additional efficiency benefits.
What the advantages and disadvantages of DBS are in toxicokinetics
How this affects the DMPK laboratory
Strategies to increase assay sensitivity for low-exposure compounds in DBS studies
How to choose the right card, matrix, and background
Strategies for validating and running DBS-derived studies
Dr Christopher Evans Section Head, DMPK GlaxoSmithKline King of Prussia, PA, USA
Dr Robert Plumb Senior Manager Pharmaceutical Business Operations Waters Corporation Milford, MA, USA